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AbstrAct:
It has long been speculated that common genetic variation influences the development 
of B-cell malignancy, however until recently evidence for this assertion was lacking. 
The advent of genome-wide association studies (GWAS) has allowed the search for 
this class of susceptibility allele to be conducted on a genome-wide basis. Recent 
GWAS of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) 
have identified novel disease genes for CLL and ALL and underscore the importance of 
polymorphic variation in B-cell development genes as determinants of leukemia risk.
IntroductIon
The identification of cancer susceptibility genes has 
provided for a greater understanding of the mechanisms 
of tumor biology. Furthermore, genetic associations are 
likely to prove increasingly valuable via the functional 
links  they  reveal,  either  endorsing  current  etiological 
hypotheses or suggesting novel ones that merit testing via 
gene-environment specific hypotheses.
While the familial clustering of B-cell malignancies 
was well recognized over forty years ago and a strong 
association  between  HLA  and  Hodgkin  lymphoma 
(HL) risk established in 1967 [1], it is only recently that 
concerted  efforts  have  been  directed  to  understanding 
inherited susceptibility to hematological malignancy. 
Here we discuss the impact findings from genome-
wide  association  studies  (GWAS)  are  having  on  our 
understanding  of  B-cell  chronic  lymphocytic  leukemia 
(CLL)  and  acute  lymphoblastic  leukemia  (ALL) 
development. 
InherIted genetIc susceptIbIlIty 
to cll And All
B-cell CLL (MIM 151400) accounts for ~25% of all 
leukemia and is the most common form of adult lymphoid 
malignancy in Western countries. Evidence for inherited 
genetic predisposition to CLL is provided by a seven-
fold elevated risk of CLL seen in first-degree relatives of 
CLL patients [2, 3]. Genome-wide linkage scans of CLL 
families have, however, consistently failed to identify a 
high risk disease locus for CLL locus making a polygenic 
model  of  inherited  predisposition  based  on  the  co-
inheritance of multiple low-risk alleles more likely [4, 5].
Acute lymphoblastic leukemia is the major pediatric 
cancer  in  economically  developed  countries;  precursor 
B-cell (BCP-ALL; MIM 613065) accounting for ~70% 
of  childhood  ALL.  In  contrast  to  CLL,  evidence  for 
a familial risk to ALL is weak. Data from the Swedish 
family-cancer database does, however, lend some support 
to an excess risk in relatives of patients, independent of 
the high concordance in monozygotic twins [6], which 
has  a  non-genetic,  in-utero  explanation. Although  rare 
(<5%  of  ALL),  direct  evidence  for  inherited  genetic 
susceptibility  is  provided  by  the  high  risk  of  ALL 
associated  with  Bloom’s  syndrome,  neurofibromatosis, 
ataxia  telangiectasia  and  constitutional  trisomy  21. 
While  evidence  linking  an  environmental  exposure  to 
risk  of  childhood  ALL  has  largely  been  inconsistent, 
epidemiological  data  for  an  infectious  etiology  is 
persuasive,  albeit  indirect  [7].  Implicit  in  a  model  of 
ALL having an infectious etiological basis is that ALL 
represents a rare sequelae [7] of infection with germline 
variation influencing host response.
cAndIdAte gene polymorphIsm 
studIes 
It  has  long  been  speculated  that  common 
polymorphic  variation  contributes  to  the  susceptibility 
of hematological malignancy but evidence for common 
low  risk  alleles  has  emerged  only  recently.  Numerous Oncotarget 2010; 1:  367 - 372 368 www.impactjournals.com/oncotarget
associations  have  been  proposed  from  candidate  gene 
analyses conducted throughout the past 30 years. Despite 
much research, no definitive susceptibility alleles have 
been unequivocally identified through these studies. As 
with many other diseases, positive associations have been 
reported for various polymorphisms but few of the initial 
positive results have been replicated in subsequent studies. 
The inherent statistical uncertainty of case-control studies 
involving just a few hundred cases and controls seriously 
limits the power of such studies to reliably identify genetic 
determinants conferring modest but potentially important 
risks.  Furthermore,  without  a  clear  understanding  of 
the biology of predisposition, the definition of suitable 
genes for the disease is inherently problematic making an 
unbiased approach to loci selection highly desirable.
the Advent of genome-wIde 
AssocIAtIon studIes
Recently, GWAS have proved a powerful approach 
for the identification of common, low-penetrance loci for 
cancer without prior knowledge of location and function. 
Most of these GWA studies are based on tag SNPs which 
capture  a  high  proportion  of  common  variation  in  the 
genome  through  linkage  disequilibrium  (LD).  This 
approach  is  unbiased  and  does  not  depend  upon  prior 
knowledge of function or presumptive involvement of any 
gene in disease causation. Moreover, this strategy avoids 
the possibility of missing the identification of important 
variants in hitherto unstudied genes.
genome-wIde AssocIAtIon studIes 
of cll And All
To identify common disease causing alleles for CLL 
and ALL we have recently conducted GWA studies of 
these diseases using a two-stage strategy [8-11]. In the 
first stage we compared the frequency of ~300,000 tag 
SNP genotypes in a discovery set of cases and controls 
and  the  SNPs  showing  the  strongest  associations  were 
subsequently  genotyped  in  multiple  independent  case-
control series. The two-stage strategy is highly efficient 
and  use  of  multiple  independent  case-control  series 
guarded  against  false  positives  being  reported.  Only 
P-values  of  ~1.0x10-7  are  conventionally  regarded  as 
providing evidence of significance at the genome-wide 
level.
To date we have identified 10 novel CLL risk loci 
at  2q13  (rs17483466),  2q37.1  (rs13397985,  SP140), 
6p25.3  (rs872071,  IRF4),  11q24.1  (rs735665),  15q23 
(rs7176508), and 19q13.32 (rs11083846, PRKD2) 2q37.3 
(rs757978),  8q24.21  (rs2456449),  15q21.3  (rs7169431) 
and 16q24.1 (rs305061, IRF8) [8, 10] and four risk loci for 
ALL at 7p12.2 (IKZF1, rs4132601), 10q21.2 (ARID5B, 
rs7089424)  and  14q11.2  (CEBPE,  rs2239633)  [9,  11, 
12]. Intriguingly, excluding CDKN2A, none of the genes 
implicated  by  these  GWA  scans  have  previously  been 
evaluated  in  targeted  association  studies,  emphasizing 
that the candidate gene approach was severely limited by 
inadequate knowledge of tumor biology. 
ImpAct of low-rIsk susceptIbIlIty 
Alleles to IndIvIduAl rIsk of cll 
And All
Chr Position SNP Gene Risk allele RAF OR
CLL 2q13 111,513,929 rs17483466 G 0.20 1.39
2q37.1 230,799,467 rs13397985 SP140 G 0.19 1.41
2q37.3 242,019,774 rs757978 FARP2 A 0.15 1.39
6p25.3 356,064 rs872071 IRF4 A 0.54 1.54
8q24.21 128,262,163 rs2456449 G 0.36 1.26
11q24.1 122,866,607 rs735665 A 0.21 1.45
15q21.3 54,128,188 rs7169431 A 0.12 1.36
15q23 67,806,044 rs7176508 A 0.37 1.37
16q24.1 84,533,160 rs305061 C 0.33 1.22
19q13.32 51,899,494 rs11083846 PRKD2 A 0.22 1.35
ALL 7p12.2 50,438,098 rs4132601 IKZF1 C 0.28 1.69
9p21.3 21,974,661 rs3731217 CDKN2A CDKN2B G 0.15 1.41
10q21.2 63,422,165 rs7089424 ARIDB5 C 0.34 1.65
14q11.2 22,658,897 rs2239633 CEBPE G 0.52 1.34
Abbreviations:
RAF, risk allele frequency; OR, odds ratio
Notes:
SNP positions based on build 36.3
Risk allele frequency in Europeans unless otherwise stated
Odds ratios quoted are per allele OR from primary or largest study
Table 1: CLL and ALL susceptibility loci identified through genome-wide association studies [8-12]Oncotarget 2010; 1:  367 - 372 369 www.impactjournals.com/oncotarget
While the risks of CLL and ALL associated with each 
of the 14 SNPs we identified are modest, relative risks 
1.2-1.7 per allele (Table 1) their respective contribution to 
disease incidence is significant as a high proportion of the 
population are carriers of these risk alleles. Furthermore, 
the  risk  increases  with  increasing  numbers  of  variant 
alleles and for the 2% of the population who possess 13 or 
more risk alleles the risk of CLL is increased ~8-fold [8]. 
The present data, however, provide only crude estimates of 
the overall effect on susceptibility attributable to variation 
at  these  loci.  The  effect  of  the  actual  common  causal 
variant  responsible  for  the  association,  once  identified, 
will typically be larger. Furthermore, many of the loci 
may carry additional risk variants, potentially including 
low-frequency variants with larger influences on disease 
risk. 
ImplIcAtIons of gwAs fIndIngs 
to our understAndIng of b-cell 
tumor development
The  SNP  genotyped  in  GWAS  are  not  generally 
candidates for causality, and enumeration of the causal 
variant at a specific locus can poise a significant challenge. 
While  fine-mapping  and  resequencing  is  required  to 
identify functional variant(s) the associations identified 
for CLL and ALL implicate a number of genes in the 
etiology of B-cell tumors.
On  the  assumption  of  cis-effects  GWAS  findings 
implicate  variation  in  SP140,  IRF4, PRKD2 and  IRF8 
in CLL development. IRF4 is a strong candidate for a 
CLL susceptibility gene a priori being a key regulator 
of lymphocyte development, and proliferation (Figure 1) 
[13-15].  Through  interaction  with  transcription  factors 
including PU.1, IRF4 controls the termination of pre-B-
cell receptor signaling and promotes the differentiation 
of pro-B cells to small B-cells. Furthermore, via BLIMP1 
and  BCL6,  IRF4  controls  the  transition  of  memory 
B-cells, thought to be the precursor cell type for CLL, to 
plasma cells. A model of disease etiology based on the 
causal variant influencing risk by arresting transition of 
memory  B-cells  through  decreased  IRF4  expression  is 
supported by a relationship between risk genotype and 
mRNA  expression  level;  expression  being  significantly 
associated with genotype in a dose-dependent fashion with 
lower levels being associated with risk alleles [10] (Figure 
2). IRF8 is also part of the transcriptional network which 
governs B-cell lineage, specification and differentiation, 
regulating α- and β-interferon response, immunoglobulin 
rearrangement and regulation of germinal center reaction 
[16].  Over-expression  of  IRF8  in  differentiated  B-cell 
progenitors  is  associated  with  growth  inhibition  and 
apoptosis with IFR8 knockout mice displaying reduced 
numbers of pre- and pro-B cells and increased numbers 
of myeloid cells. 
SP140/LYSp100B  is  the  lymphoid-restricted 
homolog of SP100 expressed in all mature B cells and 
plasma cell lines,  as  well  as  some T-cells. SP100  is  a 
major mediator of EBV-encoded nuclear antigen leader 
protein co-activation which is important for establishment 
of latent viral infections and B-cell immortalization [17]. 
Since SP140 expression is implicated in host response 
to immunodeficiency virus type 1 [18] it is possible that 
SP140 genotype influences CLL risk by affecting response 
to antigenic challenge. 
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While  a  role  for  PRKD2  (Protein  Kinase  D2)  in 
CLL  is  limited,  low  levels  of  PRKD2  expression  and 
autophosphorylation have been reported to be a feature 
of a number of B-cell tumors including mantle cell and 
Burkitt’s lymphoma, and ~50% of CLL/small lymphocytic 
lymphomas [19]. 
A  number  of  the  SNPs  associated  with  CLL  risk 
map to non-coding regions of the genome, most notably 
those  which  define  the  8q24.21  association.  GWAS  of 
other cancers have shown that the 128–130 Mb genomic 
interval at 8q24.21 harbors multiple independent loci with 
different tumor specificities which are distinct from the 
CLL association [20-25]. The 8q24.21 region to which 
these  cancer  associations  map  is  bereft  of  genes  and 
predicted transcripts. The colorectal and prostate cancer 
SNP rs6983267 has been shown to affect TCF4 binding 
to an enhancer for MYC, providing a mechanistic basis for 
an 8q24.21 association [26, 27]. If the 8q24.21 CLL locus 
influences risk through a similar cis-effect on differential 
MYC  expression,  the  association  is  intriguing  because 
MYC is a direct target of IRF4 in activated B-cells. 
The  strongest  association  signal  for  ALL  in  our 
GWAS and a contemporaneous GWAS conducted by other 
researchers was attained at 7p12.2 with rs4132601, which 
maps to the 3’ region of the Ikaros family zinc finger 1 
(IKZF1) gene. Ikaros proteins are master regulators of 
lymphocyte development (Figure 1) and differentiation 
plays a pivotal role in CD4 versus CD8 T-cell lineage 
commitment decisions [28, 29]. In homozygous mutant 
mice deleted for the N-terminal zinc finger DNA binding 
domain of IKZF1 loss of expression leads to arrest of 
lymphocyte  development  at  its  earliest  recognizable 
stage followed by rapid development of leukemia. The 
observation of a strong relationship between rs4132601 
genotype and IKZF1 mRNA expression level in EBV-
transformed lymphocytes is thus consistent with a model 
in which the causal variant influences risk by impacting 
on early B-cell differentiation [11] (Figure 2).
The association at 10q21.2 implicates the AT rich 
interactive domain 5B (ARID5B) gene in the etiology of 
ALL. While ARID5B has not been extensively studied 
evidence  for  ARID5B  having  a  role  in  defining  B-cell 
lineage is supported by data from homozygous knockout 
mice, which display decreased bone marrow cellularity 
and reduced numbers of B-cell progenitors [30]. 
The  14q11.2  association  with  ALL  annotates 
the  gene  encoding  CCAAT/enhancer-binding  protein, 
epsilon  (CEBPE).  CEBP  is  a  suppressor  of  myeloid 
leukemogenesis.  CEBPE  and  along  with  other CEBP 
family members is occasionally targeted by recurrent IGH 
translocations  in  BCP-ALL  [31]  suggesting  opposing 
functions of CEBP dysregulation in myeloid and lymphoid 
leukemogenesis and a role in susceptibility to ALL.
The  primary  impact  of  variation  defined  by  the 
7p12.2, 10q21.2 and 14q11.2 risk variants on ALL risk is 
for B-cell disease. The 10q21.2 (ARID5B) risk association 
however, appears to be highly selective for the subset of 
BCP-ALL with hyperdiploidy [11, 12]. 
The region of LD defining the 9p21.3 association 
encompasses  the  CDKN2A  and  CDKN2B  tumor-
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Figure 2: Relationship between lymphocyte mRNA 
expression levels of IRF4 and rs872071 genotype, 
SP140 and rs13397985 genotype, and IKZF1 and 
rs4132601 genotype. Risk alleles emboldened [10, 11] Oncotarget 2010; 1:  367 - 372 371 www.impactjournals.com/oncotarget
suppressor  genes  and  the  noncoding  antisense  RNA 
encoded  by  CDKN2BAS.  CDKN2A  encodes  both  p16 
(INK4A),  a  negative  regulator  of  cyclin-dependant 
kinases, and p14 (ARF1), an activator of p53. CDKN2A 
and  CDKN2B  are  frequently  inactivated  in  multiple 
hematological malignancies. Moreover, mono- or biallelic 
deletion of CDKN2A is one of the most frequent genetic 
events in both childhood BCP and T-ALL. Perhaps not 
surprisingly the association between 9p21.3 risk genotype 
and ALL is generic and not confined to a specific form of 
ALL. 
conclusIons 
 And future chAllenges 
GWAS have provided the first unambiguous evidence 
that common genetic variation contributes to the risk of 
developing CLL and ALL and implicate genes involved 
in transcriptional regulation and differentiation of B-cell 
progenitors  as  the  biological  basis  of  predisposition  to 
B-cell  malignancy.  Furthermore,  their  identification 
provides novel insight into disease causation of these two 
major haematological malignancies. The cell lineage of 
CLL coupled with the reciprocal familial risks between 
CLL and other B-cell LPDs including HD and non-Hodgkin 
lymphoma suggests that the variants may also influence 
the risk of other related B-cell LPDs. As the risk variants 
identified for CLL account for <10% of the familial risk 
of CLL, the prospects for identifying additional variants 
for this disease through additional GWAS should be high, 
and such studies are likely to provide further insights in 
the biology of B-cell tumors. 
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